COR · Cencora, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $321.33B | $293.96B | $262.17B | $238.59B | $213.99B | $189.89B |
| Cost of Revenue | $309.85B | $284.05B | $253.21B | $230.29B | $207.05B | $184.70B |
| Gross Profit | $11.48B | $9.91B | $8.96B | $8.30B | $6.94B | $5.19B |
| R&D | - | - | - | - | - | - |
| SG&A | $6.49B | $5.66B | $5.31B | $4.85B | $3.59B | $2.77B |
| Total Operating Expenses | $6.09B | - | - | - | - | - |
| D&A | $1.05B | $1.09B | $963.90M | $693.89M | $505.17M | $391.06M |
| Operating Income | $2.63B | $2.18B | $2.34B | $2.37B | $2.35B | ($5.14B) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $690.52M | $484.70M | $428.26M | $516.52M | $677.25M | ($1.89B) |
| Net Income | $1.55B | $1.51B | $1.75B | $1.70B | $1.54B | ($3.41B) |
| EPS - Basic | $8.02 | $7.60 | $8.62 | $8.15 | $7.48 | ($16.65) |
| EPS - Diluted | $7.96 | $7.53 | $8.53 | $8.04 | $7.39 | ($16.65) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.36B | $3.13B | $2.59B | $3.39B | $2.55B | $4.60B |
| Accounts Receivable | $25.23B | $23.87B | $20.91B | $18.45B | $18.17B | $13.85B |
| Inventory | $20.49B | $19.00B | $17.45B | $15.56B | $15.37B | $12.59B |
| Accounts Payable | $54.72B | $50.94B | $45.84B | $40.19B | $38.01B | $31.71B |
| Current Assets | $52.24B | $47.72B | $42.80B | $39.59B | $38.80B | $33.06B |
| Total Assets | $76.59B | $67.10B | $62.56B | $56.56B | $57.34B | $44.27B |
| Current Liabilities | $57.82B | $54.28B | $48.83B | $43.48B | $41.36B | $33.85B |
| Long-term Debt | $7.54B | $3.81B | $4.15B | $4.63B | $6.38B | $3.62B |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $1.51B | $645.94M | $522.00M | ($211.56M) | $223.35M | ($1.02B) |
| Retained Earnings | $6.53B | $5.42B | $4.32B | $2.98B | $1.67B | $518.34M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.88B | $3.48B | $3.91B | $2.70B | $2.67B | $2.21B |
| Investing Cash Flow | ($4.98B) | ($618.10M) | ($2.60B) | ($368.44M) | ($6.14B) | ($379.87M) |
| Financing Cash Flow | $2.25B | ($2.33B) | ($2.22B) | ($1.75B) | $1.95B | ($603.62M) |
| CapEx | $667.98M | $487.17M | $458.36M | $496.32M | $438.22M | $369.68M |
| Free Cash Flow | $3.21B | $3.00B | $3.45B | $2.21B | $2.23B | $1.84B |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 3.6% | 3.4% | 3.4% | 3.5% | 3.2% | 2.7% |
| Operating margin | 0.8% | 0.7% | 0.9% | 1.0% | 1.1% | -2.7% |
| EBITDA margin | 1.1% | 1.1% | 1.3% | 1.3% | 1.3% | -2.5% |
| Net margin | 0.5% | 0.5% | 0.7% | 0.7% | 0.7% | -1.8% |
| Free cash flow margin | 1.0% | 1.0% | 1.3% | 0.9% | 1.0% | 1.0% |
| FCF / Net income | 2.06 | 1.99 | 1.98 | 1.30 | 1.45 | -0.54 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 2.0% | 1.9% | 2.0% | 2.0% | 1.7% | 1.5% |
| Effective tax rate | 30.8% | 24.3% | 19.7% | 23.3% | 30.5% | - |
| Return on assets | 2.0% | 2.2% | 2.8% | 3.0% | 2.7% | -7.7% |
| Return on equity | 103.1% | 233.6% | 334.3% | -803.0% | 689.5% | 334.5% |
| Return on invested capital | 20.1% | 36.9% | 40.3% | 41.0% | 24.7% | -156.1% |
| Liquidity | ||||||
| Current ratio | 0.90 | 0.88 | 0.88 | 0.91 | 0.94 | 0.98 |
| Quick ratio | 0.55 | 0.53 | 0.52 | 0.55 | 0.57 | 0.60 |
| Cash ratio | 0.08 | 0.06 | 0.05 | 0.08 | 0.06 | 0.14 |
| Leverage | ||||||
| Debt / Equity | 5.00 | 5.90 | 7.94 | -21.90 | 28.58 | -3.55 |
| Debt / Assets | 0.10 | 0.06 | 0.07 | 0.08 | 0.11 | 0.08 |
| Debt / EBITDA | 2.05 | 1.17 | 1.25 | 1.51 | 2.23 | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 50.79 | 103.88 | 119.84 | -267.35 | 256.71 | -43.45 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 4.20 | 4.38 | 4.19 | 4.22 | 3.73 | 4.29 |
| Inventory turnover | 15.12 | 14.95 | 14.51 | 14.80 | 13.47 | 14.67 |
| Days sales outstanding | 29d | 30d | 29d | 28d | 31d | 27d |
| Days inventory outstanding | 24d | 24d | 25d | 25d | 27d | 25d |
| Days payable outstanding | 64d | 65d | 66d | 64d | 67d | 63d |
| Cash conversion cycle | -12d | -11d | -12d | -11d | -9d | -11d |
| Valuation | ||||||
| P / E | 39.3x | 29.9x | 21.1x | 16.8x | 16.2x | - |
| P / B | 40.5x | 69.8x | 70.5x | - | 111.5x | - |
| P / S | 0.2x | 0.2x | 0.1x | 0.1x | 0.1x | 0.1x |
| EV / EBITDA | 17.4x | 14.0x | 11.6x | 9.7x | 10.1x | - |
| Growth | ||||||
| Revenue growth (YoY) | 9.3% | 12.1% | 9.9% | 11.5% | 12.7% | 5.7% |
| Revenue CAGR (3y) | 10.4% | 11.2% | 11.4% | 9.9% | 8.4% | 7.4% |
| Revenue CAGR (5y) | 11.1% | 10.4% | 9.3% | 9.3% | 7.8% | 6.9% |
| Gross profit growth (YoY) | 15.8% | 10.6% | 8.0% | 19.5% | 33.7% | 1.0% |
| Operating income growth (YoY) | 20.8% | -7.1% | -1.1% | 0.5% | - | - |
| Net income growth (YoY) | 3.0% | -13.5% | 2.7% | 10.3% | - | - |
| EPS growth (YoY) | 5.7% | -11.7% | 6.1% | 8.8% | - | - |
| EPS CAGR (3y) | -0.3% | 0.6% | - | 25.8% | -0.6% | - |
| EPS CAGR (5y) | - | 13.3% | 2.5% | 37.4% | 3.2% | - |
| FCF growth (YoY) | 7.0% | -13.2% | 56.5% | -1.0% | 21.3% | -9.7% |
| FCF CAGR (5y) | 11.8% | 8.1% | 26.3% | 16.3% | -3.9% | -13.0% |
| Book value growth (YoY) | 133.5% | 23.7% | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-09-30.
Business segments
$309.68B totalUSHealthcare Solutions$285.29B · 92.1%
International Healthcare Solutions$24.39B · 7.9%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Comparing Cencora against the 5 most active filers in the same SIC group.
Dividends
$2.35/share trailing 12 months · +8.8% YoY
| Ex-date | Per share |
|---|---|
| May 15, 2026 | $0.6000 |
| Feb 13, 2026 | $0.6000 |
| Nov 14, 2025 | $0.6000 |
| Aug 15, 2025 | $0.5500 |
| May 16, 2025 | $0.5500 |
| Feb 14, 2025 | $0.5500 |
| Nov 15, 2024 | $0.5500 |
| Aug 9, 2024 | $0.5100 |
| May 9, 2024 | $0.5100 |
| Feb 8, 2024 | $0.5100 |
| Nov 10, 2023 | $0.5100 |
| Aug 10, 2023 | $0.4850 |
| May 11, 2023 | $0.4850 |
| Feb 9, 2023 | $0.4850 |
| Nov 10, 2022 | $0.4850 |
| Aug 12, 2022 | $0.4600 |
| May 13, 2022 | $0.4600 |
| Feb 11, 2022 | $0.4600 |
| Dec 1, 2021 | $1.2700 |
| Nov 12, 2021 | $0.4600 |
| Sep 29, 2021 | $1.2700 |
| Aug 13, 2021 | $0.4400 |
| Jun 29, 2021 | $1.2700 |
| May 14, 2021 | $0.4400 |